Letter to Veterinarians About Adverse Events Reported For Librela
The FDA issued a letter to veterinarians about adverse events reported since Librela’s approval in May 2023. It has been used in Europe since 2020
These events include:
- ataxia (abnormal gait)
- seizures
- paresis (weakness during movement)
- recumbency (tendency to remain laying down)
- urinary incontinence
- polyuria (increased urination) and polydipsia (increased drinking)
These reactions were seen in the older population of pet’s on Librela where concurrent disease processes and other medication administration are common
Librela removes pain from our patients which makes them more comfortable and therefore more active. When pets haven’t been active for an extended period of time and then suddenly become much more active, they can injure themselves which can sometimes present as ataxia, paresis, and recumbency.
It is important to gradually increase activity for pet’s receiving Librela to avoid this instance. Zoetis has provided a document outlining the recommended return to play plan. You can find a recommended return to play plan here.
urinary incontinence and PU/PD can occur with use of Librela but generally resolves after medication administration has stopped
We take our patient’s safety very seriously and carefully evaluate each patient to see if Librela is an acceptable therapy
For additional information visit this page.
Do not hesitate to contact us with questions or concerns
January and February: Dental Health Months
Dental health is so important to overall health! Receive 10% off your pet’s dental procedure when scheduled for a day in January or February. Keep your pet healthy, happy, and pain free, schedule now!